EGFR and non-small cell lung carcinoma: However, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) therapy recently achieved promising successes in NSCLC patients harboring EGFR active mutations [3–5], significantly prolonging patients’ survival [6,7].